BioSpace News Archive

Halozyme Therapeutics, Inc. announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint.

Genentech, a member of the Roche Group, announced longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed that patients who were treated with Ocrevus® continuously for six years or more had reduced risk of disability progression in relapsing MS and primary progressive MS.

A new, two-minute screening technique could help save cats from dying prematurely of heart disease.

InterCure, announced that subsidiary Canndoc has entered into a strategic distribution agreement with Salomon, Levin, Elstein which is owned by Teva Pharmaceuticals Industries.

Study Highlights the Utility of Bacterial Fluorescence Imaging to Provide Real-Time Information to Clinicians on a Wound’s Bacterial Burden that Significantly Impacted Treatment Decisions

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented new results from an analysis of the UK Biobank – a prospective cohort study with genetic, physical, and health data on approximately 500,000 individuals across the United Kingdom – demonstrating a significant association of the V122I mutation, a highly prevalent mutation in the transthyretin (TTR) gene, with a clinical diagnosis of polyneuropathy.

Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) is pleased to announce that it has been named as a winner in the 2019 ANZLF Trans-Tasman Innovation & Growth Awards.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, “Biogen”) today announced the decision to discontinue the Phase III clinical studies (MISSION AD1, AD2) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) in patients with early Alzheimer’s disease (AD).

Third Coast Therapeutics, a biotechnology company dedicated to developing orally active, small-molecule drugs, is pleased to announce its chief executive officer, Joseph Luminiello, was named a 2019 Notable Entrepreneur by Crain’s Chicago Business

PanTheryx, a biotechnology company, today announced that it has appointed Dr. Mehmet C. Oz, MD, surgeon and talk show host “Dr. Oz” from The Dr. Oz Show, to the company’s board of directors.